Lead compounds discovered from libraries: part 2.

Many lead compounds with the potential to progress to viable drug candidates have been identified from libraries during the past two years. There are two key strategies most often employed to find leads from libraries: first, high-throughput biological screening of corporate compound collections; and second, synthesis and screening of project-directed libraries (i.e. target-based libraries). Numerous success stories, including the discovery of several clinical candidates, testify to the utility of chemical library collections as proven sources of new leads for drug development.

[1]  G. Chiosis,et al.  Selective Cleavage of D-Ala-D-Lac by Small Molecules: Re-Sensitizing Resistant Bacteria to Vancomycin , 2001, Science.

[2]  A. Kuki,et al.  Identification of alkylidene hydrazides as glucagon receptor antagonists. , 2001, Journal of medicinal chemistry.

[3]  S. Wilhelm,et al.  Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.

[4]  G. Trainor,et al.  CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships. , 2002, Bioorganic & medicinal chemistry letters.

[5]  J. Livingston,et al.  Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis. , 2002, Bioorganic & medicinal chemistry letters.

[6]  J. Y. Roberge,et al.  Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck). , 2002, Bioorganic & medicinal chemistry letters.

[7]  J. Barrow,et al.  Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[8]  D. Hazuda,et al.  Combinatorial synthesis of CCR5 antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[9]  G. Trainor,et al.  Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. , 2002, Journal of medicinal chemistry.

[10]  Sung Soo Kim,et al.  Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents. , 2002, Bioorganic & medicinal chemistry letters.

[11]  K. Tsao,et al.  2-Aryl indole NK1 receptor antagonists: optimisation of indole substitution. , 2001, Bioorganic & medicinal chemistry letters.

[12]  J. Sullivan,et al.  Structure-Activity studies for a novel series of tricyclic dihydropyrimidines as K(ATP) channel openers (KCOs). , 2002, Bioorganic & medicinal chemistry letters.

[13]  Astrid A. Ortiz,et al.  Dihydropyridine neuropeptide Y Y(1) receptor antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[14]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[15]  D. Boger,et al.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Dolle.  Comprehensive survey of combinatorial library synthesis: 2001. , 2002, Journal of combinatorial chemistry.

[17]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[18]  Ruth Lehr,et al.  Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). , 2002, Journal of medicinal chemistry.

[19]  E. Pinard,et al.  4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[20]  Y. Yang,et al.  Potent nonpeptide GnRH receptor antagonists derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side-chain terminus. , 2001, Bioorganic & medicinal chemistry letters.

[21]  D. Boger,et al.  Erythropoietin mimetics derived from solution phase combinatorial libraries. , 2002, Journal of the American Chemical Society.

[22]  W. Greenlee,et al.  Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. , 2001, Journal of medicinal chemistry.

[23]  A Ganesan,et al.  Recent developments in combinatorial organic synthesis. , 2002, Drug discovery today.

[24]  M. Maccoss,et al.  Substituted imidazoles as glucagon receptor antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[25]  Hong Guo,et al.  Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[26]  C. Swain,et al.  2-Aryl indole NK(1) antagonists: optimisation of the amide substituent. , 2001, Bioorganic & medicinal chemistry letters.

[27]  R. Campbell,et al.  Focused library approach for identification of new N-acylphenylalanines as VCAM/VLA-4 antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[28]  R. DeVita,et al.  A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor. , 2001, Journal of medicinal chemistry.

[29]  J. S. Johnson,et al.  p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas. , 2001, Bioorganic & Medicinal Chemistry Letters.

[30]  I. McLay,et al.  The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. , 2001, Bioorganic & medicinal chemistry.

[31]  C. Janson,et al.  1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). , 2001, Bioorganic & medicinal chemistry letters.

[32]  J. S. Johnson,et al.  Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. , 2001, Bioorganic & medicinal chemistry letters.

[33]  S E Hagen,et al.  4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. , 2001, Journal of medicinal chemistry.

[34]  M. Walker,et al.  High-throughput synthesis optimization of sulfonamide NPY Y5 antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[35]  M. Fujita,et al.  Synthesis and bioactivities of novel 4,5,6,7-Tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-α (TNF-α) production , 2002 .

[36]  W. Greenlee,et al.  Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. , 2002, Journal of medicinal chemistry.

[37]  S. Rosenberg,et al.  New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models. , 2001, Journal of medicinal chemistry.

[38]  N. Ling,et al.  Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. , 2001, Journal of medicinal chemistry.

[39]  Y. Yang,et al.  Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[40]  R. Gregg,et al.  Beta 3 agonists. Part 1: evolution from inception to BMS-194449. , 2001, Bioorganic & medicinal chemistry letters.

[41]  K. Tsao,et al.  2-Aryl indole NK1 receptor antagonists: optimisation of the 2-aryl ring and the indole nitrogen substituent. , 2001, Bioorganic & medicinal chemistry letters.

[42]  M. Maccoss,et al.  The discovery of sulfonylated dipeptides as potent VLA-4 antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[43]  D. Denis,et al.  Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. , 2001, Bioorganic & medicinal chemistry.

[44]  J. Proudfoot.  Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.

[45]  Punit Marathe,et al.  Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. , 2002, Journal of medicinal chemistry.

[46]  M. Maccoss,et al.  The discovery of small molecule carbamates as potent dual α4β1/α4β7 integrin antagonists , 2002 .

[47]  S. Mccombie,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. , 2001, Bioorganic & medicinal chemistry letters.

[48]  S. Bhagwat,et al.  Structure-activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[49]  W. F. Hoffman,et al.  Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[50]  R. Dolle.  Comprehensive survey of combinatorial library synthesis: 2000. , 2001, Journal of combinatorial chemistry.

[51]  J. Madwed,et al.  Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. , 2002, Journal of medicinal chemistry.

[52]  G. Chang,et al.  Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. , 2002, Current opinion in drug discovery & development.

[53]  J. Livingston,et al.  Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[54]  A. K. Forrest,et al.  Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. , 2002, Journal of medicinal chemistry.

[55]  E. Leahy,et al.  Optimization of a screening lead for factor VIIa/TF. , 2001, Bioorganic & medicinal chemistry letters.

[56]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.

[57]  Martin R. Johnson,et al.  Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). , 2002, Journal of medicinal chemistry.

[58]  Yuan Cheng,et al.  A combinatorial library of indinavir analogues and its in vitro and in vivo studies. , 2002, Bioorganic & medicinal chemistry letters.

[59]  L. Chu,et al.  SAR studies of novel 5-substituted 2-arylindoles as nonpeptidyl GnRH receptor antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[60]  D. Auld,et al.  Targeting signal transduction with large combinatorial collections. , 2002, Drug discovery today.

[61]  J. Barrow,et al.  Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1). , 2002, Bioorganic & medicinal chemistry letters.

[62]  J. S. Johnson,et al.  Discovery of a new class of p38 kinase inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[63]  M. Maccoss,et al.  The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[64]  A Golebiowski,et al.  Lead compounds discovered from libraries. , 2001, Current opinion in chemical biology.

[65]  K. Chapman,et al.  Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. , 2002, Bioorganic & medicinal chemistry letters.

[66]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[67]  J. P. Shea,et al.  Design, synthesis, and evaluation of opioid analogues with non-peptidic beta-turn scaffold: enkephalin and endomorphin mimetics. , 2002, Journal of medicinal chemistry.

[68]  Herbert Waldmann,et al.  From protein domains to drug candidates – natural products as guiding principles in , 2002 .

[69]  D. Denis,et al.  Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry. , 2001, Bioorganic & medicinal chemistry letters.

[70]  Y. Satoh,et al.  Novel potent antagonists of human neuropeptide Y-Y5 receptor. Part 4: tetrahydrodiazabenzazulene derivatives. , 2002, Bioorganic & medicinal chemistry letters.

[71]  Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1). , 2002, Bioorganic & medicinal chemistry letters.

[72]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[73]  N. Chen,et al.  Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists. , 2001, Journal of medicinal chemistry.

[74]  Stephen D Pickett,et al.  An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors. , 2002, Journal of medicinal chemistry.

[75]  B. Katz,et al.  Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. , 2001, Journal of medicinal chemistry.

[76]  F. Cohen,et al.  Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. , 2002, Journal of medicinal chemistry.

[77]  Kevin Dinnell,et al.  2‐Aryl Indole NK1 Receptor Antagonists: Optimization of the 2‐Aryl Ring and the Indole Nitrogen Substituent. , 2001 .

[78]  J. Boehm,et al.  Phenoxypyrimidine inhibitors of p38alpha kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles. , 2001, Bioorganic & medicinal chemistry letters.

[79]  Y. Satoh,et al.  Novel potent antagonists of human neuropeptide Y Y5 receptor. Part 1: 2-oxobenzothiazolin-3-acetic acid derivatives. , 2002, Bioorganic & medicinal chemistry letters.

[80]  C. Derian,et al.  Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide. , 2001, Bioorganic & medicinal chemistry letters.

[81]  D. Denis,et al.  Structure–Activity Relationship of Biaryl Acylsulfonamide Analogues on the Human EP3 Prostanoid Receptor , 2002 .

[82]  T. Lovenberg,et al.  Aminopyrazoles with high affinity for the human neuropeptide Y5 receptor. , 2001, Bioorganic & medicinal chemistry letters.

[83]  R. McGuire,et al.  The first potent and selective inhibitors of the glycine transporter type 2. , 2001, Journal of medicinal chemistry.

[84]  W G Laver,et al.  Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. , 2001, Journal of medicinal chemistry.

[85]  K. Lyons,et al.  Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. , 2001, Bioorganic & medicinal chemistry letters.

[86]  R G Smith,et al.  Initial structure-activity relationship of a novel class of nonpeptidyl GnRH receptor antagonists: 2-arylindoles. , 2001, Bioorganic & medicinal chemistry letters.

[87]  R A Smith,et al.  Discovery and parallel synthesis of a new class of cathepsin K inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[88]  L. Kuo,et al.  Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'. , 2002, Bioorganic & medicinal chemistry letters.

[89]  W. Wilkison,et al.  Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. , 2001, Bioorganic & medicinal chemistry letters.

[90]  T. Lovenberg,et al.  Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity. , 2001, Bioorganic & medicinal chemistry letters.

[91]  Hong Guo,et al.  Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides. , 2002, Bioorganic & medicinal chemistry letters.

[92]  B. Katz,et al.  4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[93]  A. Mathur,et al.  BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptor. , 2001, Bioorganic & medicinal chemistry letters.

[94]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[95]  A. Gomtsyan,et al.  Pyridopyrimidine analogues as novel adenosine kinase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[96]  D. Hazuda,et al.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. , 2001, Bioorganic & medicinal chemistry letters.

[97]  K L Morand,et al.  The identification and characterization of hydrazinyl urea-based antibacterial agents through combinatorial chemistry. , 2001, Bioorganic & medicinal chemistry letters.

[98]  J. Davide,et al.  Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase. , 2001, Bioorganic & medicinal chemistry letters.

[99]  T. Hughes,et al.  1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2002, Journal of medicinal chemistry.

[100]  G. Bollag,et al.  Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.

[101]  M. Saunders,et al.  3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). , 2001, Bioorganic & medicinal chemistry letters.

[102]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Paul J Edwards,et al.  Solid-phase compound library synthesis in drug design and development. , 2002, Current opinion in drug discovery & development.

[104]  M. Maccoss,et al.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. , 2001, Bioorganic & medicinal chemistry letters.

[105]  J. Nielsen,et al.  Combinatorial synthesis of natural products. , 2002, Current opinion in chemical biology.

[106]  P. Taylor,et al.  Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. , 2002, Angewandte Chemie.